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B
ACKGROUND: Alpha-fetoprotein (AFP) has been 
used for hepatocellular carcinoma (HCC) diagnosis 
and screening, however, AFP has poor speciicity. 
The extensive hypervascularity associated with HCC could 
be driven in part by the pro-angiogenic factor known as 
vascular endothelial growth factor (VEGF). Furthermore, 
invasiveness of certain HCC lesions has recently been 
linked to high levels of VEGF. Therefore, circulating VEGF 
levels of patients with  liver cirrhosis (LC) and HCC were 
investigated and analysed.
METHODS: An analytical cross sectional study was 
designed. Diagnosis of HCC and LC was performed 
using clinical criteria and indings obtained from B-mode 
ultrasonography (USG), computed tomography (CT) 
angiography, or magnetic resonance imaging (MRI). Blood 
were collected intravenously from all subjects. Obtained 
serum and plasma were stored in -80°C for following 
analyses: hepatitis B surface antigen (HBSAg), hepatitis 
C virus (HCV), alanine aminotransferase (ALT), total 
bilirubin, albumin, VEGF and AFP.
RESULTS: Levels of VEGF and AFP were signiicantly 
higher in HCC group compared with LC group with p = 
3.05 x 10-6 and p = 8.74 x 10-5, respectively. There was a 
L
ATAR BELAKANG: Alpha-fetoprotein (AFP) 
telah digunakan untuk skrining hepatocellular 
carcinoma (HCC), tetapi spesiisitas AFP kurang 
baik. Hipervaskularitas yang luas terkait HCC dapat 
dikendalikan oleh faktor pro-angiogenik yang dikenal 
sebagai vascular endothelial growth factor (VEGF). Selain 
itu, tingkat invasif pada lesi HCC tertentu, berkaitan dengan 
konsentrasi VEGF yang tinggi. Oleh karena itu, konsentrasi 
VEGF yang bersirkulasi pada pasien dengan liver cirrhosis 
(LC)  dan HCC diteliti dan dianalisis. 
METODE: Studi dengan desain potong lintang analitik 
dilakukan. Diagnosis HCC dan LC dilakukan menggunakan 
kriteria klinis dan temuan yang diperoleh dari B-mode 
ultrasonography (USG), computed tomography (CT) 
angiography, atau magnetic resonance imaging (MRI). 
Darah diambil secara intravena dari semua subyek dan 
diproses. Serum dan plasma yang didapatkan disimpan 
pada suhu -80°C untuk analisis sebagai berikut: hepatitis B 
surface antigen (HBSAg), hepatitis C virus (HCV), alanine 
aminotransferase (ALT), total bilirubin, albumin, VEGF 
dan AFP.
HASIL: Konsentrasi VEGF dan AFP secara signiikan 
lebih tinggi pada grup HCC dibandingkan dengan grup 
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signiicant positive correlation (p=0.029, r=0.309) between 
VEGF level and tumor size in HCC group. The area under 
curve (AUC) for VEGF level in HCC and LC groups was 
0.771. In the level of median 435.6 pg/mL VEGF, the 
sensitivity was 50% and speciicity was 86%. In the level of 
199.99 pg/mL VEGF the sensitivity was 74% and speciicity 
was 76%. 
CONCLUSION: The present indings suggested that 
VEGF level could be a useful marker for the presence of 
HCC in patients with LC.
KEYWORDS: hepatocellular carcinoma, HCC, liver 
cirhosis, LC, vascular endothelial growth factor, VEGF, 
alpha-fetoprotein, AFP 
Indones Biomed J. 2014; 6(3): 167-74
Introduction
Hepatocellular carcinoma (HCC) is a hypervascular tumor. 
Abundant and tortuous blood vessels distinguish HCC from 
benign lesions in angiography.(1) Alpha-fetoprotein (AFP) 
has been used for many years as a serum marker for HCC 
diagnosis and screening (2,3), however, in some cases, AFP 
has poor speciicity in the detection of HCC (4,5). As the 
result, patients who have liver cirrhosis (LC) need regular 
examination by abdominal ultrasound and measurement 
of tumor markers for HCC screening. Since patients with 
hepatitis B virus (HBV)- or hepatitis C virus (HCV)-related 
LC are considered high risk, they should be screened every 
3-4 months. 
 Extensive hypervascularity associated with HCC is 
thought to be driven in part by the pro-angiogenic factor 
known as vascular endothelial growth factor (VEGF).
(6,7) Furthermore, invasiveness of certain HCC lesions has 
recently been linked to high levels of VEGF. This leads to 
a conclusion that there is an important relationship between 
VEGF and prognosis of HCC.(8,9) VEGF, a 34-46 kDa 
glycoprotein, has ive molecular isoforms generated by 
alternative splicing of VEGF mRNA.(10) They are 206, 
189, 165, 145, and 121 amino acid residues. VEGF121 
and VEGF165 are both secreted into the circulation, but 
VEGF165 is the predominant isoform secreted by most 
tumors including HCC.(11) Other isoforms do not enter 
the circulation in a signiicant amount, because they are 
either bound to the extracellular matrix (ECM) (VEGF145) 
or not secreted (VEGF189 and VEGF206).(12)  VEGF 
mediates the secretion and activation of enzymes involved 
in degrading the ECM. Acting on endothelial cells, VEGF 
induces expression of plasminogen activator and its inhibitor, 
urokinase receptor, matrix metalloproteinase, interstitial 
collagenase and gelatinase A. VEGF also decreases the 
levels of tissue inhibitors of metalloproteinases 1 and 2.(13) 
Furthermore, it acts as a survival factor for endothelial 
cells through inhibition of apoptosis and is essential for 
mobilization of bone marrow-derived endothelial cell 
precursors in the promotion of vascularization.(14) VEGF 
production is upregulated by several substances, including 
oxygen, steroid hormone, reactive oxygen metabolites 
and protein kinase C agonists.(15) VEGF is signiicantly 
expressed by sinusoidal endothelial cells and hepatocytes, 
whereas modest and inconstant expression has been 
reported for Kupffer cells.(16)  VEGF has been shown 
to induce the proliferation of hepatic sinusoidal cells 
through increasing expression of its receptors; fms-like 
tyrosine kinase (FLt) and fetal liver kinase (FLK-1) after 
experimental partial hepatectomy.(17) VEGF expression 
increases signiicantly during the course of liver ibrosis 
development in experimental studies and that VEGF 
participated in sinusoidal capillarization in the liver.(18) 
In addition to hepatocytes, activated hepatic stellate cells, 
which play an important role in liver ibrogenesis, have been 
shown to increase VEGF expression during activation.(19) 
LC, p = 3.05 x 10-6 dan p = 8.74 x 10-5, secara berurutan. 
Terdapat korelasi positif signiikan (p=0.029, r=0.309) 
antara konsentrasi VEGF dan ukuran tumor pada grup 
HCC. Area under curve (AUC) untuk konsentrasi VEGF 
pada grup HCC dan LC adalah 0.771. Pada konsentrasi 
median VEGF 435.6 pg/mL, sensitivitasnya adalah 50% and 
spesiisitasnya adalah 86%. Pada konsentrasi VEGF 199.99 
pg/mL, sensitivitasnya adalah 74% dan spesiisitasnya 
adalah 76%.
KESIMPULAN: Temuan pada penelitian ini menunjukkan 
bahwa konsentrasi VEGF dapat berguna menjadi penanda 
akan adanya HCC pada pasien LC.
KATA KUNCI: karsinoma hepatoselular, HCC, liver 
cirhosis, LC, vascular endothelial growth factor, VEGF, 
alpha-fetoprotein, AFP
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Methods
Establishment of neovasculature to support HCC growth 
involves many cell types as liver sinusoidal cells. Kuppfer 
cells, hepatic stellate cells and circulating endothelial 
progenitors.(20) 
 Conlicting data, however, have emerged regarding the 
ability of VEGF to predict disease progression and overall 
survival in HCC. This may be related to differences in the 
methods of measuring and reporting quantitative VEGF 
measurements. The three most commonly used methods 
are serum-based VEGF quantitation using enzyme-linked 
immunosorbent assay, tissue-based semi-quantitative 
VEGF immunohistochemistry, and tissue-based mRNA 
measurement.(6) One argument against the use of serum 
VEGF is the confounding role of platelets, which have 
been reported to release VEGF into the blood.(21,22) It was 
found that serum VEGF alone correlated with hepatic tissue 
VEGF, suggesting that serum VEGF is a useful indirect 
marker of tumor levels.(12) In recent study, the intraplatelet 
levels of some angiogenic proteins were reported elevated in 
cirrhosis, but did not discriminate between patients with and 
without HCC.(23) Thus, intraplatelet levels of angiogenic 
proteins seem unuseful as diagnostic or prognostic 
biomarkers of HCC in cirrhotic patients. 
 The aim of this study was to explore the clinical 
signiicance of circulating VEGF levels in  LC and HCC.
Study Design and Sample Collection
An analytical cross sectional study was designed. Diagnosis 
of HCC and LC was performed using clinical criteria and 
indings obtained from B-mode ultrasonography (USG), 
computed tomography (CT) angiography, or magnetic 
resonance imaging (MRI). Clinical data including number of 
nodule and tumor size, were collected. This study protocol 
was approved by the Health Research Ethics Committee, 
Faculty of Medicine, Hasanuddin University, Makassar, 
Indonesia.
Sample Preparation
Blood were collected intravenously from all subjects. 
Further process was conducted to obtain serum and 
plasma. Samples were stored in -80°C for further following 
analyses: hepatitis B surface antigen (HBSAg), HCV, 
alanine aminotransferase (ALT), total bilirubin, albumin, 
VEGF and AFP.
HBSAg, HCV, Total Bilirubin and Albumin Assays
HBSAg was measured with chemiluminescence 
microparticle immunoassay (CMIA) using Architect HBsAg 
assay (Abbott Laboratories, Abbott Park, IL, USA). HCV 
was measured with enzyme immunoassays (EIA) method 
using ABBOTT HCV EIA 2.0 (Abbott Laboratories). ALT 
was measured based on oxidation of NADH to NAD using 
Activated Alanine Amintransferase (Abbott Laboratories). 
Total Bilirubin was measured with Diazonium Salt method 
using Total Bilirubin (Abbott Laboratories). Albumin was 
measured Bromcresol Purple method using Albumin BCP 
(Abbott Laboratories).
VEGF Enzyme-linked Immunosorbent Assay (ELISA)
VEGF was measured with VEGF Human ELISA Kit 
(ab100663, Abcam, Cambridge, UK). Briely, it is an in 
vitro  ELISA for the quantitative measurement of Human 
VEGF. This assay employs an antibody speciic for Human 
VEGF coated on a 96-well plate. Standards and samples 
are pipetted into the wells and VEGF present in a sample is 
bound to the wells by the immobilized antibody. The wells 
are washed and biotinylated anti-Human VEGF antibody is 
added. After washing away unbound biotinylated antibody, 
HRP conjugated streptavidin is pipetted to the wells. The 
wells are again washed, a TMB substrate solution is added 
to the wells and color develops in proportion to the amount 
of VEGF bound. The Stop Solution changes the color from 
blue to yellow, and the intensity of the color is measured 
at 450 nm. The minimum detectable dose of VEGF is 
typically less than 10 pg/mL.  Recovery was determined by 
spiking various levels of recombinant Human VEGF into 
normal tissue lysate and cell lysate. Mean recovery is 95.58. 
This ELISA kit shows no cross-reactivity with any of the 
cytokines tested.
AFP ELISA
AFP ELISA was conducted with alpha Fetoprotein (AFP) 
Human ELISA Kit (ab108838, Abcam, Cambridge, UK). 
This kit is designed for the quantitative measurement 
of AFP levels. Briely, an AFP speciic antibody were 
precoated onto 96-well plates and blocked. Standards or 
test samples were added to the wells and subsequently an 
AFP speciic biotinylated detection antibody was added. 
Streptavidin-peroxidase complex is added visualized by 
3,3′,5,5′-Tetramethylbenzidine (TMB) substrate. TMB was 
catalyzed by the complex to produce a blue color product 
that changes into yellow after adding acidic stop solution. 
The density of yellow coloration is directly proportional 
to the amount of alpha Fetoprotein captured in plate. The 
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absorbance was read on a microplate reader at a wavelength 
of 450 nm.
Statistical Analysis 
Statistical analysis was performed using IBM SPSS 
Statistics for Windows, Version 21.0 (IBM Corp., Armonk, 
NY, USA). Receiver operating characteristic (ROC) curves 
were drawn in order to determine the best cut-off value of 
serum VEGF and to compare the accuracy of AFP with 
that of VEGF. A probability less than 0.05 was considered 
signiicant.
From 191 HCC and 204 LC patients, 50 HCC and 50 LC 
patients were selected. Studied parameters including age, 
gender, HBSAg, HCV, ALT, Total bilirubin and Albumin 
were obtained. Higher levels of ALT, Total Bilirubin were 
Results
Table 1. General characteristics of LC and HCC groups.
Parameter LC (N=50) HCC (N=50) p-value*
Age 62.2 + 9.6 60.26 + 10.11 0.327
Gender (male/female) 30/20 33/17 0.539
HBSAg (+/-) 16/34 20/30 0.410
HCV (+/-) 21/29 15/35 0.215
ALT (IU/L) 55.74 + 51.27 137.14 + 101.98 < 0.001
Total Bilirubin (mg/dL) 2.83 + 1.49 5.38 + 3.61 <0.001
Albumin (mg/dL) 3.13 + 0.35 2.9 + 0.49 0.007
*: Mann-Whitney U Test
Table 2. ELISA results of VEGF and AFP levels in LC and 
HCC groups.
Parameter LC (N=50) HCC (N=50) p-value*
VEGF (pg/mL) 3.05 x 10 -6
Mean 359.24 852.29
SD 1,437.67 977.62
Minimum 57.95 39.55
Maximum 10,209.74 4,230.67
AFP (ng/mL) 8.75 x 10 -5
Mean 9.30 4,167.42
SD 7.01 28,264.50
Minimum 1.70 2.40
Maximum 31.30 200,000.00
*: Mann-Whitney U Test
Figure 1. VEGF levels of LC and HCC groups.
Figure 2.  AFP levels of LC and HCC groups.
 Our ELISA results showed that mean of VEGF level 
in HCC group was 852.29 pg/mL while in LC group was 
359.24 pg/mL (Table 2, Figure 1). Mean of AFP level in 
found in HCC patients. On the other hand, higher levels of 
Albumin was found in LC patients. There were signiicant 
differences in ALT, Total Bilirubin and Albumin levels 
between LC and HCC groups (Table 1).
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Discussion
 Receiver Operating Characteristic (ROC) and area 
under curve (AUC) were used to calculate sensitivity and 
speciicity of VEGF and AFP levels to distinguish HCC 
from LC groups (Figure 3). The calculation were performed 
using the median value of VEGF and AFP levels of HCC 
and LC groups. The median for VEGF level in LC group 
was 80.976 pg/mL, and in HCC group was 435.970 pg/mL. 
The median AFP level in LC group was 6.8 ng/mL, and in 
HCC group was 28.0 ng/mL. The AUC for VEGF level in 
HCC and LC groups was 0.771. The AUC for AFP level 
was 0.728. In the level of median 435.6 pg/mL VEGF, the 
sensitivity was 50% and speciicity was 86%. In the level of 
199.99 pg/mL VEGF the sensitivity was 74% and speciicity 
was 76%. In the level of AFP 21.5 ng/mL the sensitivity was 
54% and speciicity was 92%. In the level of AFP 96.00 ng/
mL the sensitivity was 32% and speciicity was 100%.
VEGF plays an important role in angiogenesis of many 
cancers. It has been reported that circulating VEGF is 
associated with invasion and metastasis in HCC.(24-27) 
Although VEGF expression in HCC tissues are commonly 
investigated to estimate VEGF expression (28), currently 
both tissue and circulating VEGF level have signiicant 
predictive value for estimating overall survival in 
Parameter p-value*
Correlation 
Coefficient
Age 0.222 0.176
HBSAg 0.239 -0.170
HCV (+) 0.084 -0.246
ALT (>100 IU/L) 0.471 0.104
Bilirubin 0.399 0.122
Albumin 0.916 -0.015
Number of Nodule 0.626 -0.071
Tumor Size 0.029 0.309
Table 3. Correlation between VEGF with patient characteristics 
in HCC group.
*: Pearson and Spearman Test
Figure 3. ROC Curve and AUC of VEGF and AFP levels in 
LC and  HCC groups.
 There was a signiicant positive correlation (p=0.029, 
r=0.309) between VEGF level and tumor size in HCC group. 
However, There was not any signiicant correlation between 
VEGF level with age, HBSAg, HCV, ALT, bilirubin, 
albumin, and number of nodule (Table 3).
HCC group was 4,167.42 ng/mL while in LC group was 
9.30 ng/mL (Table 2, Figure 2). Levels of VEGF and AFP 
were signiicantly higher in HCC group compared with LC 
group with p=3.05 x 10-6 and p=8.74 x 10-5, respectively.
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